source
- Novo’s stock tumbles after two-year GLP-1 boom as AI drug-discovery startups land huge funding roundsNovo’s shares, which peaked above $140 in June 2024 during a surge in demand for its GLP-1 drugs Ozempic and Wegovy, have fallen sharply over the past two years. The decline reflects a broader mark…
- Azalea Therapeutics wins Endpoints 11 award, combines gene editing with CAR-T and raises $82 millionAzalea Therapeutics was named the winner of the Endpoints 11 2026 competition, highlighting its innovative approach in the biotech space. The company’s platform merges precise gene‑editing techniq…